Restricted emergency use approval from DCGI for Zydus’ PegIFN ‘Virafin’ to treat moderate COVID-19 in adults

In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The drug has also shown efficacy against other viral infections.

Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare said, “The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients, and we will continue to provide them access to critical therapies in this battle against COVID-19.”

In its Phase III clinical trials, the therapy had shown better clinical improvement in the patients suffering from COVID-19. During the trials, a higher proportion of patients administered with PegIFN arm were RT PCR negative by day 7. The drug ensures faster viral clearance and has several add-on advantages compared to other anti-viral agents.

As per the release, Type I interferons are the body’s first line of defence against many viral infections and Pegylated Interferon alpha-2b has been used to treat these infections successfully. Interferon alpha has also been implicated as crucial in the protection against SARS-CoV-2 in the recent publications in the leading journal Science.

Furthermore, aging reduces the body’s ability to produce Interferon Alpha in response to viral infections and may be associated with the higher mortality observed with COVID-19 in elderly patients. Virafin when given early on during infection can replace this deficiency and aid a faster recovery process.

The company acknowledged the support of BIRAC, in the development of Virafin for the treatment of COVID-19.

Phase III clinical trial data

The Phase III trials demonstrated that a higher proportion of patients in the PegIFN arm showed a two point statistically significant clinical improvement (WHO 7-point ORDINAL SCALE) on day 8 as compared to the Standard of Care (SOC arm) (80.36 per cent vs 68.18 per cent).

Clinically the hours of supplemental oxygen required was significantly lesser in the PegIFN arm and as well as the time to resolution of signs and symptoms as compared to the SOC arm (5 days vs 6 days).

The findings are in line with recently reported importance of early IFN treatment in the treatment of COVID-19 (Lu et al, Signal Transduction and Targeted Therapy (2021) 6:107)- a Nature publication.

Earlier the Phase II clinical trials study established the early safety, efficacy and tolerability of Virafin and indicated that Pegylated Interferon alpha-2b had significant statistical clinical impact on the patient suffering from moderate COVID-19 disease by reducing their viral load helping in better disease management such as reduced duration of oxygen support.

The results of the Phase II trial have been published in International Journal of Infectious Diseases [Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study, Anuja Pandit, et al., VOL 105, 516-521, APRIL 01, 2021.]